"INNOCARE PHARMA LIMITED"Announcement on Voluntary Disclosure of Soficitinib (ICP-332) Achieving the Primary Endpoint in a Phase II Study for the Treatment of Non-segmental Vitiligo

Announcement on Voluntary Disclosure of Soficitinib (ICP-332) Achieving the Primary Endpoint in a Phase II Study for the Treatment of Non-segmental Vitiligo

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment